Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19.
Melisa M ShahBrendan JoyceIan D PlumbSam SahakianLeora R FeldsteinEric BarkleyMason PaccioneJoseph DeckertDanessa SandmannMelissa Briggs HagenJacqueline L GerhartPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Among U.S. adults at risk for severe COVID-19 in Epic Cosmos, the lowest rate of hospitalization was among those receiving three or more mRNA vaccine doses and nirmatrelvir-ritonavir (aHR 0.22, 95%CI: 0.19-0.24). Adults who are at high-risk of severe COVID-19 disease, including vaccinated persons, should be considered for antiviral treatment.